Navigating Terzepatide and Telehealth Trends

This chapter explores the recent developments regarding Eli Lilly's terzepatide and its implications for compounding pharmacies and telehealth services. It highlights the challenges faced by pharmacies in sourcing supplies, the ethical concerns surrounding telehealth prescriptions, and the complexities of the biotech industry. The chapter also discusses the evolving standards of the FDA and the competitive landscape of pharmaceutical companies, particularly focusing on Alnylam Pharmaceuticals.